Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | RARB | P10826 | 3/20 | 0.34 |
| ▸ | RARG | P13631 | 3/20 | 0.34 |
| ▸ | RARA | P10276 | 2/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.32 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12604316 | 0.86 | NOTUM (0.47) | NOTUMPTGS1PTGS2ACACBRARB | |
| SCHEMBL24362693 | 0.74 | HDAC4 (0.45) | RXRA | |
| SCHEMBL31085141 | 0.74 | NOTUM (0.44) | NOTUMPTGS1PTGS2ACACBRARB | |
| SCHEMBL5659590 | 0.74 | NOTUM (0.44) | NOTUMPTGS1PTGS2ACACBRARB | |
| SCHEMBL24673929 | 0.74 | NOTUM (0.44) | NOTUMPTGS1PTGS2ACACBRARB | |
| SCHEMBL5656270 | 0.73 | NOTUM (0.43) | NOTUMPTGS1PTGS2ACACBRARB | |
| SCHEMBL16140285 | 0.72 | NOTUM (0.34) | NOTUMPTGS1PTGS2ACACBRARB | |
| SCHEMBL987763 | 0.71 | RARB (0.41) | NOTUMPTGS1PTGS2ACACBRARB | |
| SCHEMBL25496624 | 0.71 | HPGD (0.35) | NOTUMPTGS1PTGS2RARBRARG | |
| SCHEMBL25725393 | 0.71 | HPGD (0.35) | NOTUMPTGS1PTGS2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220267300-A1 | SULFONAMIDE DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2022-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267300-A1 | SULFONAMIDE DERIVATIVES AND USES THEREOF | IL1B, IL1A, CASP1 | NOTUM 1474/4885PTGS1 129/4885PTGS2 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.